Oklahoma City biotech firm to begin sickle cell anemia drug trial

Selexys Pharmaceuticals Corp. is ready to begin testing its sickle cell disease drug with patients.
FROM STAFF REPORTS Published: August 20, 2013
Advertisement
;

Selexys Pharmaceuticals Corp. is enrolling patients in a Phase 2 trial of a drug designed to treat sickle cell disease.

The Oklahoma City-based company obtained $23 million in venture capital financing last fall to help pay for clinical study.

Selexys' study will include about 175 patients nationwide. Patients randomly will receive a high dose of Selexys' SelG1 or a placebo, with or without standard treatment.

The study will examine the effectiveness of SelG1 in reducing the rate of sickle cell-related pain crises.

“With the limited therapies available to patients with sickle cell disease, this trial with a novel P-selectin inhibitor is particularly exciting,” said lead investigator Dr. Kenneth Ataga, a professor at the University of North Carolina at Chapel Hill. “Not only does it have the potential to improve the clinical outcomes in patients, its effects may be additive or synergistic with those of hydroxyurea, the only drug currently approved by the FDA for treatment of complications due to sickle cell disease.”

Sickle cell disease is the most common genetic disorder in the United States. It affects an estimated 100,000 Americans, including one in 500 blacks.



With the limited therapies available to patients with sickle cell disease, this trial with a novel P-selectin inhibitor is particularly exciting.”

Dr. Kenneth Ataga,
Lead investigator and a professor at the University of North Carolina at Chapel Hill

Trending Now


AROUND THE WEB

  1. 1
    New OSU mandate requires sexual-violence prevention training for all students
  2. 2
    Report: Sooners to play Houston in 2016 Advocare Texas Kickoff
  3. 3
    WATCH: Big 12 football coaches read mean tweets
  4. 4
    OU football: Trevor Knight ranked No. 81 in ESPN's top 100 College Football rankings
  5. 5
    Dez Bryant unhappy with contract negotiations, says so on Twitter
+ show more